What qualifications have you got? http://www.meckis.com/stmap_73ngz9i.html?viagra.tulasi.zithromax buyhealthsupplements.tk  Results of the trial are expected in November, 2016. Amarin's shares fell on Monday to a year-low of $4.50 following publication of the FDA's review. They were halted on Wednesday pending the outcome of the panel discussion.